In his career journey, Glen has been recognized as a successful entrepreneur, an author, and a mentor. His primary work involves giving business guidance to new companies that are starting up their businesses by coming up with new business tactics and development of M$As. Glen Wakeman is the chief executive officer and founder of Launchpad Holdings LLC. He founded the company in 2015. The firm provides strategic plans for amateur entrepreneurs. He is commonly known for his business development methodology steps which include: business execution, leadership power, human capital and risk management.
Having vast experience in the business sector, Glen has inspired small business owners seeking to grow their businesses. As an author, he has written journals and articles that give an insight of the business industry and also advising entrepreneurs in his writings (AffiliateDork). He frequently blogs about emerging business issues, global affairs, and business transformation. Glen has been a source of inspiration from financial economics to regulatory strategies. He has offered insightful ideas and mentored company startups company groups like Sitter Bees and Dreamfunded.
Glen Wakeman is an excellent scholar, he obtained his bachelor’s degree in economics from the University of Scranton in 1981, and in 1993 he graduated with a master’s degree in business administration (MBA) from the University of Chicago.
Wakeman is an active principal in transforming business opportunities, he provides strategic advice in raising business capital, investing and international financing programs (https://www.dailyforexreport.com/glen-wakeman-business-leader-assisting-small-start-companies/). He is a renowned entrepreneur and a significant force drive in the business industry.
Before launching Launchpad holdings, Glen worked at the GE capital for more than 20 years. While at GE, he lived in six countries and worked in 20 regions. At the company, he served in different managerial positions, where he helped in increasing the company’s revenues to billions. After he resigned at GE. He was also the president and founder of Nova Four before founding Launchpad which also provided strategic business to entrepreneurs.
More about Glen Wakeman on Twitter and LinkedIn
Amicus Therapeutics is highly passionate about its work. It is a global company in the field of biotechnology. This company is into advanced therapies for treating rare as well as orphan diseases. The company has a highly robust development pipeline that includes treatments for several genetic diseases in humans.
Migalastat is considered by Amicus Therapeutics as its lead product candidate (MarketWatch). This can be considered as personalized medicine. It is in the last stages of its development. This will be used for treating individuals who are suffering from Fabry disease. This would require genetic diagnosis. Another product candidate is SD-101. Even this is in its last stages of development. This will be the first therapy to be marketed. It can be used for the genetic connective tissue disorder known as Epidermolysis Bullosa (EB). Amicus Therapeutics is making use of its biologics along with the Chaperone-Advanced Replacement Therapy platform technologies. These are being used for developing several enzyme replacement therapy products. These can be used for Fabry disease, besides Pompe disease, as well as several other Lysosomal Storage Disorders.
The lead biologics program of Amicus Therapeutics is ATB200/AT2221. This is a Pompe disease ERT. It is to be administered along with a pharmacological chaperone.
Amicus Therapeutics offers three clinical programs. In addition, they can leverage their biologics capabilities along with platform technologies that can help in expanding their pipeline.
The biologics capabilities of Amicus Therapeutics helps to provide a unique tool that can be used for developing Enzyme Replacement Therapy products that can be used for LSDs. Presently, Amicus Therapeutics has novel ERTs already that can be used for Fabry as well as Pompe disease. Now the technology platforms can be used for creating future opportunities that can lead to novel ERT being developed for other LSDs.
Currently, Amicus Therapeutics is researching a potential protein replacement therapy. This will be used in preclinical studies for the CDKL5 deficiency. Any kind of genetic mutations on this CDKL5 gene can lead to CDKL5 protein deficiency. This disorder manifests itself as persistent seizures. These begin in infancy itself. It can lead to a severe impairment that can take place in neurological development.
More here : https://www.crunchbase.com/organization/amicus-therapeutics
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!